Laurus Labs

Hyderabad, India Founded: 2005 • Age: 21 yrs Listed Fortune India 500 · #418 India's Most Valuable
Pharmaceutical and biotechnology company
Request Access
Report Incorrect Data
Page last updated

About Laurus Labs

Laurus Labs is a publicly listed company based in Hyderabad (India) founded in 2005 by Subodh Singh. Pharmaceutical and biotechnology company. Laurus Labs has raised $229.73 million across 3 funding rounds from investors including Warburg Pincus, Aptuit and Eight Roads Ventures. The company has 12,470 employees. Laurus Labs has completed 2 acquisitions, including Laurus Bio and Richcore Lifesciences. Its chief executive, as recorded, is Subodh Singh. Its website lauruslabs.com draws about 19 thousand monthly visits. Its Indian entity Laurus Labs Limited reported revenue of ₹6,868 Cr. Its focus areas include Biopharma Outsourcing, CDMO, Small Molecules & Peptides and API Production. Its competitors include Symbiotec, Jubilant Pharma and SeQuent; 1 of its 3 listed competitors has raised funding.

Company details

Founded in 2005 and based in Hyderabad, India, operations are conducted in the pharmaceutical and biotechnology sectors. Active pharmaceutical ingredients are produced for antiretrovirals, hepatitis, oncology, cardiovascular, and anti-diabetic treatments. Generic formulations, custom synthesis solutions, veterinary APIs, and agro chemicals are also manufactured. Specialty ingredients for nutraceuticals, dietary supplements, and cosmeceutical products are developed.

Laurus Labs is ranked #418 on the Fortune India 500 (2025).

Recognitions & Rankings of Laurus Labs

Fortune India 500 2025 edition
Rank#418
Total income
₹5,685 Cr
Profit
₹358 Cr
Last year #411
India's Most Valuable Companies 2025 edition · Source: Hurun India
Valuation
₹59,440 Cr
1-year change
+93%
2024 #197 2023 #218 2022 #167
  • Headquarters Hyderabad, India
  • Employees 12,470
  • Founders Subodh Singh
  • Stage Public
  • Sectors
    Healthcare
  • Website category Health · Biotechnology and Pharmaceuticals
  • Email
    ••••••••
  • Phone
    •••• ••••
  • Website lauruslabs.com
  • Social LinkedIn X Facebook
  • Legal Name Laurus Labs Ltd.
Operational Areas
Healthcare → Biopharma Outsourcing & Drug Delivery
Key Metrics
  • Market Cap
    ₹1,28,054 Cr

    LAURUSLABS · NSE

  • Share Price
    ₹2,454.00

    +3.54% today

  • Revenue
    ₹6,813 Cr

    FY 2025-26 · +22.7% YoY

  • EBITDA
    ₹1,778 Cr

    Margin 26.1%

  • Net Profit
    ₹894 Cr

    FY 2025-26 · +216.3% YoY

  • P/E (TTM)
    94.4x

    P/B 20.9x

  • ROE
    18.2%

    ROCE 16.7%

  • Debt / Equity
    0.54

    Interest cover 13.2x

  • Total Equity Funding
    $229.73M (USD)

    in 3 rounds

  • Latest Funding Round
    $89.73M (USD), Private Equity Round

    Oct 2014

  • Investors
    Warburg Pincus

    & 2 more

  • Employee Count
    12,470
  • Investments & Acquisitions
    Laurus Bio

    & 1 more

Funding Insights of Laurus Labs

Laurus Labs has successfully raised a total of $229.73M across 3 strategic funding rounds. The most recent funding activity was a Private Equity Round of $89.73 million completed in October 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.

  • Total Funding $229.73M
  • Total Rounds 3
  • Last Round Private Equity Round — $89.73M
  • First Round $100M

    (Jun 2007)

  • Investors Count 3

All 3 funding rounds of Laurus Labs with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.

DateAmountTransaction NameValuationLead InvestorsInvestors
Oct 2014$89.73MPrivate Equity Round––
Warburg Pincus
Jun 2012$40MPrivate Equity Round––
Eight Roads Ventures
Jun 2007$100MPrivate Equity Round––
Aptuit
Valuation history

3 investors in total: 3 institutional.

Investors in Laurus Labs

Laurus Labs has secured backing from 3 investors, including venture fund and institutional investors. Prominent investors backing the company include Warburg Pincus, Aptuit and Eight Roads Ventures.

All
Venture Fund
Institutional
InvestorDescriptionFounded YearDomainLocation
Warburg Pincus
Multi-stage private equity investments are pursued across diverse sectors.
1966warburgpincus.comNew York, United States
Eight Roads Ventures
Venture capital investment and global platform support for startups.
2008eightroads.comLondon, United Kingdom
Aptuit
Contract research and development services for small molecules are offered.
2004aptuit.comGreenwich, United States
Premium access

Investor details for Laurus Labs

The complete investor list, round-by-round participation and investor portfolios require an active premium plan.

  • Complete investor list
  • Round participation
  • Investor portfolios
  • Co-investor network

Verified entity values are shown only after access is granted.

Board of directors of Laurus Labs Limited (Laurus Labs)

Laurus Labs Limited is the primary company behind Laurus Labs. The boards of the 5 registered companies of Laurus Labs currently have 18 directors; the longest-serving is Satyanarayana Chava, appointed in 2006. 40 earlier directors have ceased.

DirectorDesignationAppointedTenureEntity
Satyanarayana Chava
DIN 00211921
Whole-time director21 Jan 200620 yrs 9 moLaurus Labs Limited
Venkata Ravi Kumar Vantaram
DIN 01424180
Whole-time director30 Nov 200619 yrs 11 moLaurus Labs Limited
Ved Parkash
DIN 00021360
Managing Director15 Oct 200719 yrsLaurus Industries Private Limited
Madhu Bala Gupta
DIN 01771084
Director07 Aug 201016 yrs 3 moLaurus Industries Private Limited
Vidhul Gupta
DIN 06798683
Whole-time director15 Feb 201412 yrs 8 moLaurus Industries Private Limited
Srinivasa Rao Suryadevara
DIN 06885360
Director25 Jul 201412 yrs 3 moSriam Labs Private Limited
Ravindranath Kancherla
DIN 00117940
Director18 May 20179 yrs 5 moLaurus Labs Limited
Venkata Lakshmana Rao Chunduru
DIN 06885453
Whole-time director08 Mar 20188 yrs 8 moLaurus Labs Limited, Sriam Labs Private Limited
Sita Ramaiah Chagarlamudi
DIN 08210856
Director18 May 20206 yrs 5 moLaurus Synthesis Private Limited, Laurus Ingredients Private Limited
Venkata Lakshmi Narasimha Rao Dammalapati
DIN 03258307
Director23 Jul 20206 yrs 3 moLaurus Synthesis Private Limited, Laurus Ingredients Private Limited
Uma Maheswar Rao Vasireddi
DIN 03506390
Director23 Jul 20206 yrs 3 moSriam Labs Private Limited
Narasimha Rao Chava
DIN 08836445
Director17 Aug 20206 yrs 2 moLaurus Synthesis Private Limited
Sekar Karnam
DIN 07400094
Director25 Apr 20242 yrs 6 moLaurus Labs Limited
Krishna Chaitanya Chava
DIN 06831883
Whole-time director25 Apr 20242 yrs 6 moLaurus Labs Limited, Laurus Synthesis Private Limited, Sriam Labs Private Limited
Soumya Chava
DIN 06831892
Whole-time director25 Apr 20242 yrs 6 moLaurus Labs Limited, Laurus Synthesis Private Limited
Ramesh Subrahmanian
DIN 02933019
Director25 Jul 20242 yrs 3 moLaurus Labs Limited
Sutapa Banerjee
DIN 02844650
Director02 Jul 20264 moLaurus Labs Limited
Shekhar Chintamani Mande
DIN 10083454
Director02 Jul 20264 moLaurus Labs Limited

People of Laurus Labs

41 people are tracked at Laurus Labs (11 in leadership, 4 in board & advisors, 26 in team); the tracked headcount is 12,470.

NameRoleGroup
Subodh Singh
Founder & CEOLeadership
Rajesh Koneru
General Manager Information SystemsLeadership
Thomas Versosky
President, FDF, North AmericaLeadership
Satyanarayana Chava
Founder & CEOLeadership
V V Ravi Kumar
Executive Director & CFOLeadership
B.v.r.k.s Srinivas Rao
Vice President - OperationsLeadership
Suresh Poda
PresidentLeadership
Kameswaragupta Samayamanthula
Assistant General ManagerLeadership
Vivek Digumarti
VP & Head - ITLeadership
Naveen Venkatesham
Assistant Vice PresidentLeadership
Srihari Parupalli
Assistant General Manager - Project ManagementLeadership
Rajesh Koshy Chandy
Independent DirectorBoard & advisors
Ravindranath Kancherla
Independent DirectorBoard & advisors
Aruna Rajendra Bhinge
Independent DirectorBoard & advisors
M Venu Gopala Rao
Non-Executive Chairman & Independent DirectorBoard & advisors
Martyn Oliver James Peck
SVP, Business Development, Generics APITeam
Saivani Kunapareddy
AssociateTeam
S Srinivasa Rao
EVP, OperationsTeam
Rajaram Iyer
SVP, Portfolio ManagementTeam
Enugandula Harsha
Project ManagerTeam

21 more people are available in the full profile.

Premium access

Complete people profiles for Laurus Labs

Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.

  • Full employee list
  • Team structure
  • Board tenure
  • Professional contacts

Verified entity values are shown only after access is granted.

IPO & Listings of Laurus Labs

Laurus Labs is a publicly listed company on the NSE with ticker symbol LAURUSLABS in India, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.

  • IPO date19 Dec 2016
  • Listed onNSE: LAURUSLABS · BSE: 540222
  • Listed entityLaurus Labs Ltd.
  • Exchange sectorHealth technology
  • ISININE947Q01028
  • Share price₹2,036.90 (-1.09% on the day) · 2026-10-14
  • Market capitalisation₹110,823 Cr
  • Price to earnings100.7
  • EPS (diluted, trailing year)₹20.23
  • Dividend yield0.1%
  • Volume (last session)1,300,927

Financials of Laurus Labs

Exchange-reported figures of Laurus Labs Limited, the listed company behind Laurus Labs (NSE: LAURUSLABS).

Financial Highlights

FY 2025-26 · Consolidated
Revenue
₹6,813 Cr
+22.7% YoY
EBITDA
₹1,778 Cr
+68.5% YoY
Profit After Tax
₹894 Cr
+216.3% YoY
Net Worth
₹5,300 Cr
+18.5% YoY
Total Assets
₹8,642 Cr
+10.5% YoY
Total Debt
₹2,518 Cr
-8.9% YoY

Revenue vs Net Profit ₹ Cr

Margin trends

Financial summary ₹ Cr

MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue6,8135,5545,0416,0414,9364,8142,832
Revenue growth+22.7%+10.2%-16.6%+22.4%+2.5%+70.0%-
EBITDA1,7781,0557781,5921,4221,551565
EBITDA margin+26.1%+19.0%+15.4%+26.4%+28.8%+32.2%+19.9%
Profit before tax1,1824842361,1091,0841,301294
Net profit894283162790828984256
Net profit margin+13.1%+5.1%+3.2%+13.1%+16.8%+20.4%+9.0%
EPS (₹)16.466.642.9814.6715.4018.3323.88
Balance sheet
Total assets8,6427,8206,9356,3625,3594,3012,952
Net worth5,3004,4734,1114,0383,3512,5981,770
Total debt2,5182,7642,5772,0151,7771,4821,079
Cash & bank11414414248.4675.9448.461.74
Net working capital2,9892,8492,4402,2461,8041,6441,014
Cash flow
Cash from operations1,624602666994911733347
Cash from investing(1,086)(680)(822)(997)(914)(941)(221)
Cash from financing(525)39.28250(26.64)30.26255(128)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,2062,0261,8121,7781,6531,5701,7201,415
Revenue growth (YoY)+33.4%+29.1%+5.3%+25.7%+35.1%+31.4%--
Other income13.019.1811.805.7626.9610.4358.579.42
EBITDA750638512480403382421285
EBITDA margin+34.0%+31.5%+28.3%+27.0%+24.4%+24.3%+24.4%+20.2%
Depreciation127124122121120117110106
Interest44.1042.2240.4438.7940.0051.5056.4057.80
Profit before tax592481361327270224312131
Tax15511979.4673.4575.9863.1478.4740.07
Net profit43736228225319416123490.61
EPS (₹)8.166.815.174.653.613.024.331.71
MetricsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Income statement
Revenue6,0895,2174,8125,7734,7074,7692,797
Revenue growth+16.7%+8.4%-16.7%+22.7%-1.3%+70.5%-
EBITDA1,4389447501,4821,2851,510570
EBITDA margin+23.6%+18.1%+15.6%+25.7%+27.3%+31.7%+20.4%
Profit before tax9945043011,0519751,275304
Net profit744305224761751957268
Net profit margin+12.2%+5.8%+4.7%+13.2%+16.0%+20.1%+9.6%
EPS (₹)13.727.054.1514.1213.9617.8224.98
Balance sheet
Total assets7,9057,3086,4325,8965,1784,2552,968
Net worth5,2524,5644,2074,0573,3882,7121,816
Total debt2,0802,3802,1101,7141,6531,4111,051
Cash & bank37.8250.6442.921.7040.5638.780.93
Net working capital2,7332,7632,3482,1861,8441,6991,014
Cash flow
Cash from operations1,385540659882823694345
Cash from investing(847)(592)(757)(735)(837)(900)(217)
Cash from financing(551)59.32139(185)15.19243(127)
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,0141,7571,5801,5091,5671,4331,6501,265
Revenue growth (YoY)+28.6%+22.6%-4.2%+19.3%+32.2%+28.3%--
Other income24.7220.0713.0914.3728.4521.5272.167.12
Total expenses1,3841,2581,2051,1641,1771,1051,2551,059
EBITDA631499375346390327395206
EBITDA margin+31.3%+28.4%+23.8%+22.9%+24.9%+22.8%+23.9%+16.3%
Depreciation97.6995.7695.1794.3195.5993.5788.1988.66
Interest38.0235.2033.9131.4833.6843.8948.6048.02
Profit before tax52038825923428921133076.72
Tax13198.2167.5859.3673.1753.5078.3019.45

Financial Statements

Figures in ₹ Cr; negatives in brackets. Updated 09 Nov 2026
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,2062,0261,8121,7781,6531,5701,7201,415
Revenue growth (YoY)+33.4%+29.1%+5.3%+25.7%+35.1%+31.4%--
Other income13.019.1811.805.7626.9610.4358.579.42
EBITDA750638512480403382421285
EBITDA margin+34.0%+31.5%+28.3%+27.0%+24.4%+24.3%+24.4%+20.2%
Depreciation127124122121120117110106
Interest44.1042.2240.4438.7940.0051.5056.4057.80
Profit before tax592481361327270224312131
Tax15511979.4673.4575.9863.1478.4740.07
Net profit43736228225319416123490.61
EPS (₹)8.166.815.174.653.613.024.331.71
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue6,8135,5545,0416,0414,9364,8142,832
Revenue growth+22.7%+10.2%-16.6%+22.4%+2.5%+70.0%-
Other income54.9575.1026.346.0015.3023.665.92
Total expenses5,0354,4994,2634,4483,5133,2632,267
Employee cost815676615557470397321
EBITDA1,7781,0557781,5921,4221,551565
EBITDA margin+26.1%+19.0%+15.4%+26.4%+28.8%+32.2%+19.9%
Depreciation480430385324251205187
Interest17121618316510268.1689.59
Profit before tax1,1824842361,1091,0841,301294
Tax29213068.1531225131738.34
Net profit894283162790828984256
Net profit margin+13.1%+5.1%+3.2%+13.1%+16.8%+20.4%+9.0%
EPS (₹)16.466.642.9814.6715.4018.3323.88
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital108108108108107107107
Reserves & surplus5,1924,3654,0033,9303,2442,4901,658
Shareholders' funds (net worth)5,3004,4734,1114,0383,3512,5981,770
Minority interest1311304.6211.137.863.150.00
Secured loans1,4251,6741,9281,4251,3731,320875
Unsecured loans1,0931,090649590403161204
Total debt2,5182,7642,5772,0151,7771,4821,079
Total liabilities8,6427,8206,9356,3625,3594,3012,952
Assets
Gross block6,9436,2735,6524,8033,7553,0282,388
Net block4,3714,1233,8903,4092,6522,1711,726
Capital work in progress77345842355181336267.18
Investments30923312449.9030.813.413.41
Inventories2,3421,9371,8451,6851,7601,575905
Sundry debtors2,1552,0071,6631,5801,3541,306791
Cash & bank balances11414414248.4675.9448.461.74
Loans & advances218244185148154145114
Total current assets4,8294,3323,8353,4623,3453,0751,812
Total current liabilities1,8401,4841,3951,2161,5401,431799
Net working capital2,9892,8492,4402,2461,8041,6441,014
Total assets8,6427,8206,9356,3625,3594,3012,952
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash99.5413945.6775.3548.461.692.97
Net cash from operating activities1,624602666994911733347
Net cash from investing activities(1,086)(680)(822)(997)(914)(941)(221)
Net cash from financing activities(525)39.28250(26.64)30.26255(128)
Net change in cash13.12(39.40)93.27(29.68)26.8946.77(1.28)
Closing cash11414414248.4675.9448.461.74
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+22.7%+10.2%-16.6%+22.4%+2.5%+70.0%-
EBITDA growth+68.5%+35.7%-51.2%+11.9%-8.3%+174.7%-
PBT growth+144.0%+104.9%-78.7%+2.3%-16.7%+343.1%+145.2%
Net income growth+216.3%+74.9%-79.5%-4.6%-15.8%+284.6%-
Revenue CAGR (3Y)+4.1%+4.0%+1.6%+28.7%+29.1%+32.8%+14.1%
EBITDA CAGR (3Y)+3.7%-9.5%-20.6%+41.3%+58.7%+55.4%+11.5%
Profitability & leverage
Net income margin+13.1%+6.4%+3.3%+13.2%+16.9%+20.4%+9.0%
Return on capital employed+16.7%+8.8%+6.3%+21.8%+24.6%+37.8%+13.6%
Return on net worth+18.2%+6.5%+4.1%+21.6%+28.0%+45.1%+15.3%
Debt / equity0.540.620.560.510.550.590.64
Long-term debt / equity0.150.180.200.190.180.150.13
Interest cover13.1634.5546.5513.028.745.0723.75
Efficiency & per share
Fixed asset turnover1.030.930.961.411.461.781.26
Inventory turnover3.182.942.863.512.963.883.57
Debtors turnover3.273.033.114.123.714.593.77
EPS (₹)16.466.642.9814.6715.4018.3323.88
Dividend per share (₹)2.001.200.802.002.002.002.50
Book value per share (₹)98.1882.9476.2874.9662.3748.41165.11
ParticularsSep 2026Jun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024
Revenue2,0141,7571,5801,5091,5671,4331,6501,265
Revenue growth (YoY)+28.6%+22.6%-4.2%+19.3%+32.2%+28.3%--
Other income24.7220.0713.0914.3728.4521.5272.167.12
Total expenses1,3841,2581,2051,1641,1771,1051,2551,059
EBITDA631499375346390327395206
EBITDA margin+31.3%+28.4%+23.8%+22.9%+24.9%+22.8%+23.9%+16.3%
Depreciation97.6995.7695.1794.3195.5993.5788.1988.66
Interest38.0235.2033.9131.4833.6843.8948.6048.02
Profit before tax52038825923428921133076.72
Tax13198.2167.5859.3673.1753.5078.3019.45
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Revenue6,0895,2174,8125,7734,7074,7692,797
Revenue growth+16.7%+8.4%-16.7%+22.7%-1.3%+70.5%-
Other income77.4310047.4215.9521.5527.325.81
Total expenses4,6514,2734,0634,2923,4223,2592,227
Employee cost684571532478418365300
EBITDA1,4389447501,4821,2851,510570
EBITDA margin+23.6%+18.1%+15.6%+25.7%+27.3%+31.7%+20.4%
Depreciation379359345301235197184
Interest14318215114695.8665.9287.71
Profit before tax9945043011,0519751,275304
Tax25412377.7729122531937.43
Net profit744305224761751957268
Net profit margin+12.2%+5.8%+4.7%+13.2%+16.0%+20.1%+9.6%
EPS (₹)13.727.054.1514.1213.9617.8224.98
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Equity & liabilities
Share capital108108108108107107107
Reserves & surplus5,1444,4564,0993,9493,2812,6051,709
Shareholders' funds (net worth)5,2524,5644,2074,0573,3882,7121,816
Secured loans1,0301,3251,4801,1341,2611,257847
Unsecured loans1,0501,054630580392155204
Total debt2,0802,3802,1101,7141,6531,4111,051
Total liabilities7,9057,3086,4325,8965,1784,2552,968
Assets
Gross block5,3654,8794,7064,2223,2542,6572,341
Net block3,0412,8883,0362,8842,1861,8181,694
Capital work in progress56933615635775532466.53
Investments89174063538436231958.32
Inventories2,1361,7391,6971,5691,6891,534893
Sundry debtors2,0232,0351,6401,4871,2691,280778
Cash & bank balances37.8250.6442.921.7040.5638.780.93
Loans & advances165182137113206189112
Total current assets4,3634,0073,5173,1713,2053,0411,785
Total current liabilities1,6301,2431,1709861,3601,343771
Net working capital2,7332,7632,3482,1861,8441,6991,014
Total assets7,9057,3086,4325,8965,1784,2552,968
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Opening cash50.3642.631.4240.3338.780.880.51
Net cash from operating activities1,385540659882823694345
Net cash from investing activities(847)(592)(757)(735)(837)(900)(217)
Net cash from financing activities(551)59.32139(185)15.19243(127)
Net change in cash(12.85)7.7341.21(38.91)1.5537.900.37
Closing cash37.8250.6442.921.7040.5638.780.93
ParticularsFY 2025-26FY 2024-25FY 2023-24FY 2022-23FY 2021-22FY 2020-21FY 2019-20
Growth
Sales growth+16.7%+8.4%-16.7%+22.7%-1.3%+70.5%-
EBITDA growth+52.3%+25.9%-49.4%+15.3%-14.9%+164.8%-
PBT growth+97.3%+67.1%-71.3%+7.8%-23.5%+318.6%+151.2%
Net income growth+144.2%+35.8%-70.5%+1.3%-21.5%+257.4%-
Revenue CAGR (3Y)+1.8%+3.5%+0.3%+27.3%+28.2%+33.0%+13.9%
EBITDA CAGR (3Y)-1.0%-9.8%-20.8%+37.5%+54.1%+54.6%+11.3%
Profitability & leverage
Net income margin+12.2%+7.3%+4.7%+13.2%+15.9%+20.1%+9.6%
Return on capital employed+15.0%+9.1%+7.3%+21.6%+22.7%+37.1%+13.9%
Return on net worth+15.1%+6.9%+5.4%+20.4%+24.6%+42.2%+15.7%
Debt / equity0.450.510.460.450.500.540.60
Long-term debt / equity0.090.110.140.160.160.130.13
Interest cover13.4931.1237.2512.349.135.0222.70
Efficiency & per share
Fixed asset turnover1.191.091.081.541.591.911.27
Inventory turnover3.143.042.953.542.923.933.59
Debtors turnover3.002.843.084.193.694.633.82
EPS (₹)13.727.054.1514.1213.9617.8224.98
Dividend per share (₹)2.001.200.802.002.002.002.50
Book value per share (₹)97.2984.6478.0675.3163.0550.54169.84

Investments & Acquisitions by Laurus Labs

Laurus Labs has strategically engaged in corporate development activities, having acquired 2 companies. Notable acquisitions include Laurus Bio and Richcore Lifesciences.

Acquisitions
Company NameDescriptionDomainLocationFoundedAcquiredAmount
Laurus Bio
Precision fermentation services for biopharma and food are provided.
laurus.bioBengaluru, India2005Sep 2023••••
Richcore Lifesciences
Developer of enzymes for industrial solutions
richcoreindia.comBengaluru, India2001Nov 2020$33.31M
Premium access

Complete acquisition details for Laurus Labs

Acquired stakes, deal sources and the complete acquisition history require an active premium plan.

  • Acquired stakes
  • Deal sources
  • Complete history
  • Exports

Verified entity values are shown only after access is granted.

Timeline of Laurus Labs

6 dated milestones of Laurus Labs across 18 years, from founding to its latest funding, stage changes and deals.

  1. Founded Laurus Labs is founded.
  2. Funding First funding round of $100.0M.
  3. Funding Latest funding round, Private Equity Round, of $89.7M.
  4. IPO Lists on the stock exchange (IPO).
  5. Acquisition Acquires Richcore Lifesciences.
  6. Acquisition Acquires Laurus Bio.

Competitors of Laurus Labs

Laurus Labs has 3 listed competitors in our database, 1 of them funded. They include Symbiotec, Jubilant Pharma and SeQuent.

Company NameDomainFoundedHQ LocationTotal fundingEmployeesDescription
Symbiotec
symbiotec.in2002Indore, India$61.01M1,822
Non-sterile steroid hormone-based APIs and intermediates are manufactured.
Jubilant Pharma
jubilantpharma.com1978Noida, India
Pharmaceuticals, APIs, and radiopharmaceuticals are manufactured by the company.
SeQuent
sequent.in2002Bengaluru, India
APIs are developed and manufactured for therapeutic areas.
Premium access

Detailed competitors of Laurus Labs

The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.

  • Full competitor set
  • Operating metrics
  • Benchmarks
  • Competitive positioning

Verified entity values are shown only after access is granted.

Web traffic of Laurus Labs

The website of Laurus Labs (lauruslabs.com) receives about 18.9K visits a month and ranks #1,732,878 among all websites worldwide, #2,350 in Biotechnology and Pharmaceuticals.

  • Monthly visits
    18.9K

    ▲ 23.6% vs previous month

  • Unique visitors
    6.4K

    per month

  • Global rank
    #1,732,878

    among all websites

  • Category rank
    #2,350

    Health · Biotechnology and Pharmaceuticals

Similar websites

Websites whose visitors overlap most with Laurus Labs. Affinity shows how closely the audiences match.

WebsiteDomainAudience affinityMonthly visitsGlobal rankProfile
eisai.co.in
eisai.co.in
100%
#9,679,406–
pharmazell.com
pharmazell.com
98%
–
Galpha Laboratories
galpha.com
89%
7K#5,128,365View details
Marksans Pharma
marksanspharma.com
54%
8K#2,963,739View details

Top companies in Biopharma Outsourcing & Drug Delivery

2 companies that operate in the same segment as Laurus Labs (Biopharma Outsourcing & Drug Delivery) in India, ranked by their profile score on The Company Check.

CompanyDescriptionFoundedLocationTotal fundingRevenueEmployees
Anthem Biosciences
Developer of integrated contract research development and manufacturing services
2007Bengaluru, Karnataka, IndiaUSD 35.74 MUSD 226.38 M2,062
Entero Healthcare
India's leading healthcare products distribution platform
2018Mumbai, Maharashtra, IndiaUSD 59.67 MUSD 702.49 M557
Upgrade to premium

Unlock complete access to The Company Check

Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.

Upgrade to Premium No viewing limits. Your plan controls exports and screening usage.
Included in your Premium account
  • ✓
    Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
  • ✓
    Full access to every database India & global coverage, advanced filters and rich profile details
  • ✓
    Always-on access from your team account Single premium plan for everything you see on the portal

Related news about Laurus Labs

LAURUSLABS: Q2 CONS NET PROFIT 4.4B RUPEES VS 1.95B (YOY); EST 3.54B
Exchange Update • 11 days ago
LAURUSLABS: Q2 EBITDA 7.5B RUPEES VS 4B (YOY), EST 6.44B; Q2 EBITDA MARGIN 34% VS 24.39% (YOY), EST 30.5%
Exchange Update • 11 days ago
Laurus Labs: Co Reports That LB-4 Fermentation Manufacturing Unit Is Advancing On Schedule (>400KL) And Will Be Ready By Q3 FY27.
Exchange Update • 11 days ago
Laurus Labs Invests ₹107.8 Crore in KRKA Pharma Through Rights Issue, Maintains 49% Ownership
Free Press Journal • 25 days ago
Laurus Labs: Invests ₹1,078 Crore In Krka Pharma Through Rights Issue To Acquire 107.8 Million Shares.
Exchange Update • 26 days ago
LAURUSLABS: RS. 61.44 CRORES BSE BLOCK TRADE; FOR ~ 302,000 SHARES, AT RS. 2034.30
Exchange Update • 1 month ago
LAURUSLABS: Rs. 24.20 Crores BSE Block Trade; for ~ 119,161 Shares, at Rs. 2031.05
Exchange Update • 1 month ago
Laurus Labs: Invests ₹12.09 Crores In Kurnool Renewables Through Rights Issue; Acquires 1.21 Crore Shares; Total Stake In KRPL Holds Steady At 26%.
Exchange Update • 1 month ago
LAURUS LABS LTD.: RS. 80.64 CRORES NSE BLOCK TRADE; FOR ~ 430,164 SHARES, AT RS. 1874.60
Exchange Update • 1 month ago
Laurus Labs' capex gamble pays off as CDMO orders drive earnings and stock surge
Moneycontrol • 1 month ago
Premium access

Complete news archive for Laurus Labs

Full article history, source details, and older brand coverage require an active premium plan.

  • Full article archive
  • Source and publication date
  • Older coverage
  • Brand-specific news history

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Laurus Labs

Laurus Labs was founded in 2005 and raised its 1st funding round 2 years after it was founded.

Laurus Labs is headquartered in Hyderabad, India. It is registered at Hyderabad, Telangana, India.

Subodh Singh is the CEO of Laurus Labs, as recorded in our data. They have also founded this company.

Laurus Labs is a funded company, having raised a total of $229.73M across 3 funding rounds to date. The company's 1st funding round was a Private Equity Round of $100M, raised on Jun 2007.

Laurus Labs has 12,470 employees.

The primary company behind Laurus Labs, Laurus Labs Limited, reported revenue of ₹6,868 Cr for FY 2026, up 23% year on year.

Founded in 2005 and based in Hyderabad, India, operations are conducted in the pharmaceutical and biotechnology sectors. Active pharmaceutical ingredients are produced for antiretrovirals, hepatitis, oncology, cardiovascular, and anti-diabetic treatments. Generic formulations, custom synthesis solutions, veterinary APIs, and agro chemicals are also manufactured. Specialty ingredients for nutraceuticals, dietary supplements, and cosmeceutical products are developed.

Laurus Labs's top competitors include Symbiotec, SeQuent and Jubilant Pharma.

Yes, Laurus Labs is publicly traded on NSE under the ticker symbol LAURUSLABS.

Laurus Labs has made 2 acquisitions, including Laurus Bio, and Richcore Lifesciences.

Laurus Labs has 3 investors. Key investors include Warburg Pincus, Aptuit, and Eight Roads Ventures.

Laurus Labs is associated with 5 legal entities: Laurus Labs Limited, Laurus Industries Private Limited, Laurus Synthesis Private Limited and others.

Explore millions of companies — effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals — all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available